Logo image of CBD

CIA BRASILEIRA DE DIS- ADR (CBD) Stock Fundamental Analysis

NYSE:CBD - New York Stock Exchange, Inc. - US20440T3005 - ADR - Currency: USD

0.445  -0.01 (-3.05%)

After market: 0.4357 -0.01 (-2.09%)

Fundamental Rating

2

CBD gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 41 industry peers in the Consumer Staples Distribution & Retail industry. CBD may be in some trouble as it scores bad on both profitability and health. CBD does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

CBD had negative earnings in the past year.
In the past year CBD had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: CBD reported negative net income in multiple years.
CBD had a positive operating cash flow in 4 of the past 5 years.
CBD Yearly Net Income VS EBIT VS OCF VS FCFCBD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 2B -2B 4B

1.2 Ratios

CBD's Return On Assets of -10.30% is on the low side compared to the rest of the industry. CBD is outperformed by 78.05% of its industry peers.
With a Return On Equity value of -48.12%, CBD is not doing good in the industry: 80.49% of the companies in the same industry are doing better.
Looking at the Return On Invested Capital, with a value of 0.48%, CBD is doing worse than 70.73% of the companies in the same industry.
Industry RankSector Rank
ROA -10.3%
ROE -48.12%
ROIC 0.48%
ROA(3y)-3.02%
ROA(5y)-0.73%
ROE(3y)-14.58%
ROE(5y)-4.12%
ROIC(3y)N/A
ROIC(5y)N/A
CBD Yearly ROA, ROE, ROICCBD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -20 -40

1.3 Margins

CBD's Operating Margin of 0.50% is on the low side compared to the rest of the industry. CBD is outperformed by 68.29% of its industry peers.
CBD's Operating Margin has declined in the last couple of years.
With a decent Gross Margin value of 25.02%, CBD is doing good in the industry, outperforming 63.41% of the companies in the same industry.
CBD's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 0.5%
PM (TTM) N/A
GM 25.02%
OM growth 3Y-54.5%
OM growth 5Y-37.57%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.29%
GM growth 5Y1.26%
CBD Yearly Profit, Operating, Gross MarginsCBD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 10 -10 20

More info and screens

1

2. Health

2.1 Basic Checks

CBD has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
The number of shares outstanding for CBD remains at a similar level compared to 1 year ago.
The number of shares outstanding for CBD has been increased compared to 5 years ago.
The debt/assets ratio for CBD is higher compared to a year ago.
CBD Yearly Shares OutstandingCBD Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M
CBD Yearly Total Debt VS Total AssetsCBD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 20B 40B 60B

2.2 Solvency

Based on the Altman-Z score of 1.07, we must say that CBD is in the distress zone and has some risk of bankruptcy.
CBD's Altman-Z score of 1.07 is on the low side compared to the rest of the industry. CBD is outperformed by 73.17% of its industry peers.
CBD has a Debt/Equity ratio of 1.72. This is a high value indicating a heavy dependency on external financing.
CBD has a worse Debt to Equity ratio (1.72) than 82.93% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.72
Debt/FCF N/A
Altman-Z 1.07
ROIC/WACC0.09
WACC5.48%
CBD Yearly LT Debt VS Equity VS FCFCBD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 5B 10B 15B

2.3 Liquidity

CBD has a Current Ratio of 1.21. This is a normal value and indicates that CBD is financially healthy and should not expect problems in meeting its short term obligations.
CBD has a Current ratio of 1.21. This is comparable to the rest of the industry: CBD outperforms 51.22% of its industry peers.
CBD has a Quick Ratio of 1.21. This is a bad value and indicates that CBD is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of CBD (0.89) is better than 70.73% of its industry peers.
Industry RankSector Rank
Current Ratio 1.21
Quick Ratio 0.89
CBD Yearly Current Assets VS Current LiabilitesCBD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 10B 20B 30B 40B

More info and screens

3

3. Growth

3.1 Past

CBD shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -1171.43%.
Looking at the last year, CBD shows a very negative growth in Revenue. The Revenue has decreased by -59.86% in the last year.
CBD shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -17.17% yearly.
EPS 1Y (TTM)-1171.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%72.55%
Revenue 1Y (TTM)-59.86%
Revenue growth 3Y-27.85%
Revenue growth 5Y-17.17%
Sales Q2Q%-69.65%

3.2 Future

The Earnings Per Share is expected to grow by 24.83% on average over the next years. This is a very strong growth
Based on estimates for the next years, CBD will show a quite strong growth in Revenue. The Revenue will grow by 8.97% on average per year.
EPS Next Y83.74%
EPS Next 2Y38.43%
EPS Next 3Y24.83%
EPS Next 5YN/A
Revenue Next Year8.97%
Revenue Next 2Y6.92%
Revenue Next 3Y6.72%
Revenue Next 5Y8.97%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
CBD Yearly Revenue VS EstimatesCBD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 20B 40B 60B 80B
CBD Yearly EPS VS EstimatesCBD Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0 2 -2 -4

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

CBD reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CBD. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CBD Price Earnings VS Forward Price EarningsCBD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, CBD is valued cheaper than 85.37% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 5
CBD Per share dataCBD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

CBD's earnings are expected to grow with 24.83% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y38.43%
EPS Next 3Y24.83%

More info and screens

5

5. Dividend

5.1 Amount

With a Yearly Dividend Yield of 13.41%, CBD is a good candidate for dividend investing.
The stock price of CBD dropped by -47.63% in the last 3 months. With lower prices the dividend yield is higher, but it may be a sign investors do not trust the long term dividend.
Compared to an average industry Dividend Yield of 2.18, CBD pays a better dividend. On top of this CBD pays more dividend than 100.00% of the companies listed in the same industry.
CBD's Dividend Yield is rather good when compared to the S&P500 average which is at 2.44.
Industry RankSector Rank
Dividend Yield 13.41%

5.2 History

The dividend of CBD decreases each year by -24.04%.
CBD has paid a dividend for at least 10 years, which is a reliable track record.
Dividend Growth(5Y)-24.04%
Div Incr Years0
Div Non Decr Years0
CBD Yearly Dividends per shareCBD Yearly Dividends per shareYearly Dividends per share 2015 2016 2018 2019 2020 2021 2022 0.5 1 1.5 2

5.3 Sustainability

CBD has negative earnings and hence a negative payout ratio. The dividend may be in danger.
DP-4.93%
EPS Next 2Y38.43%
EPS Next 3Y24.83%
CBD Yearly Income VS Free CF VS DividendCBD Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 1B -1B 2B -2B

More info and screens

CIA BRASILEIRA DE DIS- ADR

NYSE:CBD (4/18/2024, 8:04:00 PM)

After market: 0.4357 -0.01 (-2.09%)

0.445

-0.01 (-3.05%)

Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupConsumer Staples Distribution & Retail
GICS IndustryConsumer Staples Distribution & Retail
Earnings (Last)02-21 2024-02-21/bmo
Earnings (Next)05-01 2024-05-01/amc
Inst Owners0.12%
Inst Owner Change-40.88%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap218.06M
Analysts50
Price Target1.53 (243.82%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 13.41%
Yearly Dividend0.41
Dividend Growth(5Y)-24.04%
DP-4.93%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-273.86%
Min EPS beat(2)-455.83%
Max EPS beat(2)-91.89%
EPS beat(4)0
Avg EPS beat(4)-228.76%
Min EPS beat(4)-455.83%
Max EPS beat(4)-25.58%
EPS beat(8)0
Avg EPS beat(8)-362.44%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-3.9%
Min Revenue beat(2)-4.34%
Max Revenue beat(2)-3.47%
Revenue beat(4)0
Avg Revenue beat(4)-27.12%
Min Revenue beat(4)-59.79%
Max Revenue beat(4)-3.47%
Revenue beat(8)2
Avg Revenue beat(8)-9.38%
Revenue beat(12)3
Avg Revenue beat(12)-9.97%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-19.66%
PT rev (3m)-10.73%
EPS NQ rev (1m)54.81%
EPS NQ rev (3m)58.85%
EPS NY rev (1m)49.53%
EPS NY rev (3m)46.14%
Revenue NQ rev (1m)-0.72%
Revenue NQ rev (3m)-1.13%
Revenue NY rev (1m)0.22%
Revenue NY rev (3m)-1.27%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.06
P/FCF N/A
P/OCF 1.99
P/B 0.24
P/tB 0.41
EV/EBITDA 5
EPS(TTM)-0.86
EYN/A
EPS(NY)-0.14
Fwd EYN/A
FCF(TTM)-0.24
FCFYN/A
OCF(TTM)0.22
OCFY50.28%
SpS7.65
BVpS1.88
TBVpS1.09
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -10.3%
ROE -48.12%
ROCE 0.61%
ROIC 0.48%
ROICexc 0.63%
ROICexgc 0.76%
OM 0.5%
PM (TTM) N/A
GM 25.02%
FCFM N/A
ROA(3y)-3.02%
ROA(5y)-0.73%
ROE(3y)-14.58%
ROE(5y)-4.12%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y-58.82%
ROICexcg growth 5Y-42.48%
ROICexc growth 3Y-57.55%
ROICexc growth 5Y-42.78%
OM growth 3Y-54.5%
OM growth 5Y-37.57%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.29%
GM growth 5Y1.26%
F-Score2
Asset Turnover0.87
Health
Industry RankSector Rank
Debt/Equity 1.72
Debt/FCF N/A
Debt/EBITDA 6.59
Cap/Depr 103.08%
Cap/Sales 6.08%
Interest Coverage 250
Cash Conversion 45.66%
Profit Quality N/A
Current Ratio 1.21
Quick Ratio 0.89
Altman-Z 1.07
F-Score2
WACC5.48%
ROIC/WACC0.09
Cap/Depr(3y)82.81%
Cap/Depr(5y)104.8%
Cap/Sales(3y)7.75%
Cap/Sales(5y)7.55%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1171.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%72.55%
EPS Next Y83.74%
EPS Next 2Y38.43%
EPS Next 3Y24.83%
EPS Next 5YN/A
Revenue 1Y (TTM)-59.86%
Revenue growth 3Y-27.85%
Revenue growth 5Y-17.17%
Sales Q2Q%-69.65%
Revenue Next Year8.97%
Revenue Next 2Y6.92%
Revenue Next 3Y6.72%
Revenue Next 5Y8.97%
EBIT growth 1Y-87.1%
EBIT growth 3Y-67.17%
EBIT growth 5Y-48.29%
EBIT Next Year586.28%
EBIT Next 3Y102.85%
EBIT Next 5Y76.66%
FCF growth 1Y66.99%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y360.65%
OCF growth 3Y-50.85%
OCF growth 5Y-33.31%